London, UK, 14 May 2007, Curidium Medica Plc, (LSE: CUR), the personalized medicine company focused on bringing the right drug to the right patient, today announced it has developed a blood diagnostic test that can sub-classify patients with schizophrenia/bipolar disorder into one of four subgroups. This is the first time that a schizophrenia/bipolar disorder diagnostic blood test has been developed that classifies patients into different subgroups that are each associated with distinct underlying disease mechanisms and specific drug targets. The discovery, using Curidium's proprietary technology Homomatrix®, of highly statistically significantly different schizophrenic/bipolar disease patient subgroups was announced previously by the Company.
